What's new? Log in Free sign up

Kineta (KA) News and press releases

Company Profile

News

From Benzinga Pro

Kineta To Host KOL Event To Review New Data From VISTA-101 Clinical Trial Of KVA12123 In Patients With Advanced Solid Tumors On December 5, 2023

Biotech, News, General

Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will host a virtual KOL

Kineta Unveils New Data From VISTA-101 Clinical Trial Of KVA12123 At The Society For Immunotherapy Of Cancer's 38th Annual Meeting

Biotech, News, Events, General

Favorable Clinical Safety and Tolerability Profile Observed with No Evidence of CRS-associated Cytokines Achieved Greater Than Dose-Proportional PharmacokineticsBiomarker Results Demonstrate Robust VISTA Target

Kineta Q3 2023 EPS $(0.46) Up From $(1.14) YoY

THIRD QUARTER AND YEAR-TO-DATE 2023 FINANCIAL HIGHLIGHTSCash position: As of September 30, 2023, cash was $7.6 million, compared to $13.1 million as of December 31, 2022. The decrease was primarily due to cash used

Kineta Presents New Preclinical Data On Lead Anti-CD27 Monoclonal Antibody At The Society For Immunotherapy Of Cancer' 38th Annual Meeting

Biotech, News, Events, General

Lead Anti-CD27 Monoclonal Antibody Showed High Binding Affinity and SpecificityDrives Strong T Cell Activation and Proliferation as well as NK Cell ActivationDemonstrated In Vivo Antitumor Efficacy as a Single Agent and

Kineta Announces First Patient Dosed In Phase 1/2 VISTA-101 Clinical Trial Of KVA12123 In Combination With KEYTRUDA In Patients With Advanced Solid Tumors

Biotech, News, General

The Combination Arm (Part B) of the Phase 1/2 Clinical Trial Builds Upon the Initial Safety, Tolerability and Pharmacokinetic Data of KVA12123 in the Monotherapy Arm (Part A)Initial Combination Therapy Clinical Data

Watching Kineta, Inc.; Zacks Small-Cap Research Sets $13.50 Price Valuation

News, Analyst Ratings, Trading Ideas

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_10122023_KA_Vandermosten.pdf

Kineta Announces KVA12123 And Anti-CD27 Agonist Antibody Abstracts Accepted For Poster Presentations At Society For Immunotherapy Of Cancer 2023; Shares Halted On Circuit Breaker To The Upside

Biotech, News, Events, Trading Ideas, General

Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that two abstracts have been

Nasdaq Rises 100 Points; RPM International Posts Upbeat Earnings

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets, Trading Ideas

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling over 50 points on Wednesday. The Dow traded down 0.24% to 32,924.47 while the NASDAQ rose 0.77% to 13,159.47. The S&P 500 also rose, gaining, 0.15% to 4,235.65.

Why Cal-Maine Foods Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) jumped 95.2% to $3.7280. Gaucho Group is planning to list two of its retail properties in Argentina, in San Rafael and Cordoba, for sale, priced at $2 million and $0.7 million respectively.

Crude Oil Falls Sharply; ISM Services PMI Declines In September

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets, Trading Ideas

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1% on Wednesday. The Dow traded up 0.28% to 33,094.01 while the NASDAQ rose 1.08% to 13,200.09. The S&P 500 also rose, gaining, 0.55% to 4,252.74.

US Stocks Rise Following ADP Data; Dow Rises Over 50 Points

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Intraday Update, Markets, Trading Ideas

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 50 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.17% to 33,059.59 while the NASDAQ rose 0.33% to 13,102.96. The S&P 500 also rose, gaining, 0.22% to 4,238.68.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Kineta Presents New Preclinical Data On Lead Anti-CD27 Agonist Antibody At AACR Special Conference On Tumor Immunology And Immunotherapy

Biotech, News, Events, General

Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the presentation of new preclinical

Top 5 Health Care Stocks That May Plunge In October

News, Penny Stocks, Short Ideas, Small Cap, Pre-Market Outlook, Markets, Trading Ideas

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Kineta, Inc. Announces $3M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

News, Offerings

Kineta, Inc. (NASDAQ:KA) (the "Company" or "Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Kineta Announces KVA12123 Monotherapy Safety And Biomarker Data From Its Ongoing Phase 1/2 VISTA-101 Clinical Trial

Biotech, News, General

Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose Level>90% VISTA Receptor Occupancy Observed in the 30 mg Dosing CohortVISTA Blocking

Kineta To Present New Preclinical Data On Lead Anti-CD27 Agonist Antibody At AACR Special Conference On Tumor Immunology And Immunotherapy

Biotech, News, Events, General

Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present a poster on the

Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Kineta Announces New Research Agreement To Evaluate VISTA Biomarker Expression

Biotech, News, General

Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today a research agreement with Fred

Press releases

From Benzinga Pro

Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023

News, Press Releases

SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,

Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit

News, Press Releases

SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,

Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Health Care, Press Releases

Favorable Clinical Safety and Tolerability Profile Observed with No Evidence of CRS-associated Cytokines Achieved Greater Than Dose-Proportional Pharmacokinetics Biomarker Results Demonstrate Robust VISTA Target

Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Earnings, Press Releases

Announced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in combination with pembrolizumab in patients with advanced solid tumors

Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

News, Press Releases

Lead Anti-CD27 Monoclonal Antibody Showed High Binding Affinity and Specificity Drives Strong T Cell Activation and Proliferation as well as NK Cell Activation Demonstrated In Vivo Antitumor Efficacy as a Single Agent

Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

The Combination Arm (Part B) of the Phase 1/2 Clinical Trial Builds Upon the Initial Safety, Tolerability and Pharmacokinetic Data of KVA12123 in the Monotherapy Arm (Part A) Initial Combination Therapy Clinical

Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023

News, Press Releases

SEATTLE, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,

Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023

News, Health Care, Press Releases, General

SEATTLE, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,

Kineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

News, Financing, Press Releases

SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA) (the "Company" or "Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address

Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Health Care, Press Releases

SEATTLE, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA) (the "Company" or "Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address

Kineta Announces Participation at October Investor Conferences

News, Press Releases

SEATTLE, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,

Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy

Health Care, Press Releases

SEATTLE, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,

Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression

Health Care, Press Releases

SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.